OncoMatch/Clinical Trials/NCT06771518
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Is NCT06771518 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Atezolizumab 1200 mg e.v. q21 for small cell lung cancer.
Treatment: Atezolizumab 1200 mg e.v. q21 — Investigate the role of consolidative radiotherapy treatment at the thoraco-mediastinal level in the patient suffering from lung microcytoma - extensive disease and treated with chemo-immunotherapy with atezolizumab, in association with maintenance therapy with atezolizumab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage EXTENDED DISEASE
Extended disease at the time of first line oncological treatment
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemoimmunotherapy — first line
chemoimmunotherapy according to the Impower 133 scheme
Cannot have received: radiation therapy
Exception: thoraco-mediastinal level only
Previous radiotherapy treatment at the thoraco-mediastinal level
Lab requirements
Blood counts
Haematological toxicity ≤ G1
Haematological, respiratory toxicity ≤ G1, other toxicities ≤ G2 at the time of treatment radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06771518 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage EXTENDED DISEASE is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages